AHS Cancer Control Alberta

🇨🇦Canada
Ownership
Private
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

PET/MRI in Rectal Cancer

First Posted Date
2023-09-28
Last Posted Date
2024-06-12
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
40
Registration Number
NCT06057831

Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1)

Phase 2
Not yet recruiting
Conditions
Arthralgia
Arthritis
Interventions
Drug: Methotrexate
First Posted Date
2023-08-21
Last Posted Date
2024-06-12
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
27
Registration Number
NCT06001125

SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases

First Posted Date
2023-03-20
Last Posted Date
2024-06-21
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
24
Registration Number
NCT05775146
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer

Phase 2
Recruiting
Conditions
Prostate Cancer
Oncology
Interventions
Drug: [18]F-PSMA-1007
First Posted Date
2023-02-03
Last Posted Date
2024-01-30
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
248
Registration Number
NCT05712174
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

PSMA-PET/CT Registry

Terminated
Conditions
Prostate Cancer
Interventions
Diagnostic Test: [18F]-PSMA-1007
First Posted Date
2023-02-02
Last Posted Date
2024-12-18
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
128
Registration Number
NCT05709535
Locations
🇨🇦

Tom Baker Cancer Centre/Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada

Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

First Posted Date
2022-12-23
Last Posted Date
2024-06-12
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
20
Registration Number
NCT05663775
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma

Phase 1
Not yet recruiting
Conditions
Mycosis Fungoides
Interventions
Drug: Cemiplimab
First Posted Date
2022-09-14
Last Posted Date
2024-06-14
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
16
Registration Number
NCT05538988
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

Participating in Tai Chi to Reduce Anxiety and Keep up Physical Function

Not Applicable
Active, not recruiting
Conditions
Prostate Cancer
Interventions
Other: Tai Chi Prehabilitation
Other: Usual care
First Posted Date
2022-07-11
Last Posted Date
2024-01-30
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
40
Registration Number
NCT05452824
Locations
🇨🇦

Prostate Cancer Centre, Calgary, Alberta, Canada

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

First Posted Date
2022-07-11
Last Posted Date
2024-06-12
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
62
Registration Number
NCT05451043
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

Pilot Trial for Treatment of Recurrent Glioblastoma

First Posted Date
2022-06-27
Last Posted Date
2024-06-03
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
10
Registration Number
NCT05432518
Locations
🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy